Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221188 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
A Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
- 6
- Study locations
NCT07221188: Recruiting Phase 3 study of Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline.
NCT07221188 is a Phase 3 study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,250 participants, above the 155-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (706% higher). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221188, a Phase 3 study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efimosfermin Alfa
Study Locations (6)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Ocala
Texas
- GSK Investigational Site - San Antonio
- GSK Investigational Site - Waco
Missouri
- GSK Investigational Site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2028-03-24 |
| Phase | Phase 3 |
What NCT07221188 shows while recruiting
NCT07221188 is an interventional study that assigns participants to a tested intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, above the 155-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (706% higher).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07221188 lists 6 locations in 3 states (Florida, Texas, Missouri).
Frequently Asked Questions
What is clinical trial NCT07221188 about?
NCT07221188 is a clinical study titled "A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH". This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
What is the current status of trial NCT07221188?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2025-12-12. Estimated completion is 2028-03-24.
What conditions does trial NCT07221188 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT07221188?
The interventions under investigation include: Placebo (DRUG), Efimosfermin Alfa (DRUG).
Who is sponsoring clinical trial NCT07221188?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221188 being conducted?
This trial has 6 study locations across Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07221188's enrollment target sits among peer trials
1,250 1st of 57 the highest of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
ACTIVE NOT RECRUITING · Phase 3
-
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
COMPLETED · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
- NCT06024395 · 1,250 participants · NA
A Stepped Care Approach to Treating Dental Fear
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI